• TMEM16F Lipid Scrambling Modulates Ferroptosis and Tumor Imm

  2026-06-17

  The referenced study uncovers TMEM16F-mediated lipid scrambling as a critical regulator suppressing ferroptosis by remodeling plasma membrane phospholipids. Inhibiting TMEM16F not only potentiates ferroptotic cell death but also enhances tumor immune rejection, offering new mechanistic insight and therapeutic potential for cancer immunotherapy.

• Guidelines for Diagnosis and Treatment of Cutaneous Candidia

  2026-06-17

  This article analyzes the clinical guideline paper by Kato (2009), which provides a comprehensive framework for the diagnosis and topical management of mucocutaneous candidiasis, particularly focusing on the role of imidazole antifungals such as Neticonazole Hydrochloride. The review highlights diagnostic strategies, classification schemes, and evidence-backed topical therapy, with implications for translational research and experimental modeling.

• DIDS in Metastatic Reprogramming: Mechanistic Insights and A

  2026-06-16

  Explore how DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) uniquely modulates chloride and TRPV1 channels, with implications for metastatic reprogramming and neuroprotection. This article offers an in-depth, evidence-based analysis not found in standard overviews.

• Generation of Functional Hepatobiliary Organoids from hiPSCs

  2026-06-16

  Wu et al. established a robust protocol for producing hepatobiliary organoids from human induced pluripotent stem cells (hiPSCs), recapitulating key aspects of liver development without genetic modification or exogenous cell input. This model offers a significant advance for studying human liver organogenesis and facilitates drug discovery and disease modeling in vitro.

• Trelagliptin Promotes Osteoblastic Differentiation via RUNX2

  2026-06-15

  The reference study demonstrates that Trelagliptin, a DPP-4 inhibitor, enhances osteoblastic differentiation in MC3T3-E1 cells through upregulation of RUNX2 via AMPK signaling. These findings introduce a potential therapeutic avenue for osteoporosis and highlight the importance of precise cell preparation in translational bone research.

• Toremifene in Breast Cancer: 20 Years of Clinical Insights

  2026-06-15

  This review analyzes two decades of clinical data on toremifene, a selective estrogen receptor modulator (SERM), for the treatment of hormone-sensitive breast cancer. The paper highlights efficacy, safety, and the evolving context of endocrine therapies, with implications for biomarker-driven and personalized approaches in breast cancer research.

• P2RX1 Drives Mitochondrial Apoptosis in Ph+ ALL via Ca2+/CaM

  2026-06-14

  This study uncovers how P2RX1 overexpression sensitizes Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) cells to mitochondrial apoptosis by modulating intracellular calcium and suppressing PI3K/Akt signaling. The findings provide mechanistic insight into apoptosis regulation in TKI-resistant leukemia and highlight potential therapeutic targets.

• Toremifene and Advances in Endocrine Therapy for Breast Canc

  2026-06-13

  This review examines 20 years of clinical and translational data on toremifene, a selective estrogen receptor modulator (SERM), in hormone-sensitive breast cancer. It highlights key innovations in personalized medicine, the comparative landscape of SERMs and aromatase inhibitors, and the implications for biomarker-driven therapy selection.

• Two Decades of Toremifene in Breast Cancer: Clinical Insight

  2026-06-12

  This review analyzes 20 years of clinical data on toremifene, a selective estrogen receptor modulator (SERM) used in hormone-sensitive breast cancer. Key findings center on its efficacy, safety, and unique pharmacokinetics relative to tamoxifen and aromatase inhibitors, informing treatment personalization and biomarker-driven therapy selection.

• Field Comparison of UAV and Knapsack Sprayer Pesticide Drift

  2026-06-12

  This study provides a quantitative field assessment of pesticide spray drift produced by unmanned aerial vehicles (UAVs) versus traditional electric knapsack sprayers (EKS), using Rhodamine B as a fluorescent tracer. The findings reveal that UAVs generate substantially greater drift distances and deposition rates, offering critical guidance for environmental risk assessment and regulatory policy in agricultural practice.

• Indole-3-pyruvic Acid: Protocols and Innovations in Bench Re

  2026-06-11

  Indole-3-pyruvic acid (IPA) enables precise control in both plant hormone and immunology workflows, bridging advanced auxin biosynthesis modeling and translational disease studies. This article delivers stepwise protocols, troubleshooting insights, and unique assay guidance inspired by recent mechanistic discoveries, establishing IPA from APExBIO as an essential research tool.

• Exo1 for Membrane Trafficking Inhibition: Protocols & Insigh

  2026-06-11

  Exo1 (methyl 2-(4-fluorobenzamido)benzoate) enables acute, ARF1-specific exocytic pathway inhibition, setting it apart from legacy agents for membrane trafficking studies. Its distinct mechanism and rapid action provide superior temporal control in exocytosis and extracellular vesicle assays.

• Single-Cell Insights Reveal BCL-2 as a Target in CRPC Hetero

  2026-06-10

  This study integrates single-cell imaging, mechanistic modeling, and a Phase Ib clinical trial to validate BCL-2 as a therapeutic target across heterogeneous castration-resistant prostate cancer (CRPC) subtypes. The findings highlight how androgen receptor (AR) pathway inhibition induces BCL-2, revealing a vulnerability that spans both AR+ and AR-/lo prostate cancer cell populations.

• Cyclo (-RGDfC): Precision αvβ3 Integrin Targeting for Cancer

  2026-06-10

  Cyclo (-RGDfC) is a cyclic peptide with high specificity for the integrin αvβ3 receptor, enabling robust tumor targeting and reproducible cell adhesion assays. Its stability and molecular precision make it a preferred reagent for angiogenesis research and integrin-mediated signaling studies.

• Phosbind Acrylamide: Precision Tools for Phosphorylation Res

  2026-06-09

  Protein phosphorylation is central to cellular signaling and disease, but traditional detection methods struggle with specificity, throughput, and dynamic range. This thought-leadership article explores how Phos binding reagent (Phosbind) acrylamide, an advanced phosphate-binding reagent from APExBIO, empowers translational researchers to resolve complex phosphorylation events—especially in the context of PTM crosstalk such as O-GlcNAcylation—without antibody limitations. Drawing on recent mechanistic insights, we examine strategic experimental approaches, competitive technologies, and translational implications in neuroscience and oncology.

14462 records 1/965 page Next 12345 下5页 Last page